Larry G. Edwards
Chief Executive Officer en Aicuris Anti-Infective Cures AG .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Peter Kleinhenz | M | - |
Clarametyx Biosciences, Inc.
Clarametyx Biosciences, Inc. BiotechnologyHealth Technology Clarametyx Biosciences, Inc. operates as a biotechnology company. It develops a dynamic pipeline of immune-enabling therapies and vaccines for chronic and recurrent bacterial infections. The company was founded by Michael Triplett, Peter G. Kleinhenz, Juliana Woda, and Charles McOsker and is headquartered in Columbus, OH. | - |
Michael Triplett | M | - |
Clarametyx Biosciences, Inc.
Clarametyx Biosciences, Inc. BiotechnologyHealth Technology Clarametyx Biosciences, Inc. operates as a biotechnology company. It develops a dynamic pipeline of immune-enabling therapies and vaccines for chronic and recurrent bacterial infections. The company was founded by Michael Triplett, Peter G. Kleinhenz, Juliana Woda, and Charles McOsker and is headquartered in Columbus, OH. | - |
Craig Johnson | M | 62 | 11 años | |
Morten Otto Sommer | M | 43 |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | 6 años |
Chirfi Guindo | M | 58 | 13 años | |
Tom Glocer | M | 63 | 17 años | |
Rasmus Toft-Kehler | M | - |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | 6 años |
Charles McOsker | M | - |
Clarametyx Biosciences, Inc.
Clarametyx Biosciences, Inc. BiotechnologyHealth Technology Clarametyx Biosciences, Inc. operates as a biotechnology company. It develops a dynamic pipeline of immune-enabling therapies and vaccines for chronic and recurrent bacterial infections. The company was founded by Michael Triplett, Peter G. Kleinhenz, Juliana Woda, and Charles McOsker and is headquartered in Columbus, OH. | - |
Holger Zimmermann | M | - |
Aicuris Anti-Infective Cures AG
Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The private company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | 9 años |
Helga Rübsamen-Schaeff | M | 75 |
Aicuris Anti-Infective Cures AG
Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The private company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | 18 años |
Peter Aksel Villadsen | M | - |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | 6 años |
Thomas Hadley | M | - |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | 4 años |
Kevin Tang | M | 57 | 10 años | |
Peter Wendell | M | 73 | 21 años | |
Stefan Oschmann | M | 66 |
Aicuris Anti-Infective Cures AG
Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The private company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | 21 años |
Dalton Smart | M | 58 | 15 años | |
David Richards | M | - |
Clarametyx Biosciences, Inc.
Clarametyx Biosciences, Inc. BiotechnologyHealth Technology Clarametyx Biosciences, Inc. operates as a biotechnology company. It develops a dynamic pipeline of immune-enabling therapies and vaccines for chronic and recurrent bacterial infections. The company was founded by Michael Triplett, Peter G. Kleinhenz, Juliana Woda, and Charles McOsker and is headquartered in Columbus, OH. | - |
Tony Hodges | M | - | 3 años | |
Allan Gabor | M | - | 11 años | |
Michael Layman | M | 32 |
Clarametyx Biosciences, Inc.
Clarametyx Biosciences, Inc. BiotechnologyHealth Technology Clarametyx Biosciences, Inc. operates as a biotechnology company. It develops a dynamic pipeline of immune-enabling therapies and vaccines for chronic and recurrent bacterial infections. The company was founded by Michael Triplett, Peter G. Kleinhenz, Juliana Woda, and Charles McOsker and is headquartered in Columbus, OH. | - |
Pavel Raifeld | M | 40 | 2 años | |
Steven Graziano | M | - | 18 años | |
Veronica L. Hall | M | - |
Clarametyx Biosciences, Inc.
Clarametyx Biosciences, Inc. BiotechnologyHealth Technology Clarametyx Biosciences, Inc. operates as a biotechnology company. It develops a dynamic pipeline of immune-enabling therapies and vaccines for chronic and recurrent bacterial infections. The company was founded by Michael Triplett, Peter G. Kleinhenz, Juliana Woda, and Charles McOsker and is headquartered in Columbus, OH. | - |
Wayne L. Embree | M | - |
Clarametyx Biosciences, Inc.
Clarametyx Biosciences, Inc. BiotechnologyHealth Technology Clarametyx Biosciences, Inc. operates as a biotechnology company. It develops a dynamic pipeline of immune-enabling therapies and vaccines for chronic and recurrent bacterial infections. The company was founded by Michael Triplett, Peter G. Kleinhenz, Juliana Woda, and Charles McOsker and is headquartered in Columbus, OH. | - |
Juliana Woda | M | - |
Clarametyx Biosciences, Inc.
Clarametyx Biosciences, Inc. BiotechnologyHealth Technology Clarametyx Biosciences, Inc. operates as a biotechnology company. It develops a dynamic pipeline of immune-enabling therapies and vaccines for chronic and recurrent bacterial infections. The company was founded by Michael Triplett, Peter G. Kleinhenz, Juliana Woda, and Charles McOsker and is headquartered in Columbus, OH. | 4 años |
Denise Williams | F | - | 15 años | |
Pamela Eisele | F | - | 15 años | |
Sanat Chattopadhyay | M | - | 15 años | |
Marianne Zhen | F | 55 | 2 años | |
James Matteucci | M | - | 21 años | |
Richard DeLuca | M | 61 | 13 años | |
Alan Roemer | M | 54 |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | 4 años |
Sean Marett | M | 59 |
Aicuris Anti-Infective Cures AG
Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The private company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | 3 años |
Charles Bramlage | M | 63 |
Clarametyx Biosciences, Inc.
Clarametyx Biosciences, Inc. BiotechnologyHealth Technology Clarametyx Biosciences, Inc. operates as a biotechnology company. It develops a dynamic pipeline of immune-enabling therapies and vaccines for chronic and recurrent bacterial infections. The company was founded by Michael Triplett, Peter G. Kleinhenz, Juliana Woda, and Charles McOsker and is headquartered in Columbus, OH. | - |
Bill Baumel | M | 55 |
Clarametyx Biosciences, Inc.
Clarametyx Biosciences, Inc. BiotechnologyHealth Technology Clarametyx Biosciences, Inc. operates as a biotechnology company. It develops a dynamic pipeline of immune-enabling therapies and vaccines for chronic and recurrent bacterial infections. The company was founded by Michael Triplett, Peter G. Kleinhenz, Juliana Woda, and Charles McOsker and is headquartered in Columbus, OH. | - |
Andrew Davis | M | 38 |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | 5 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 91 | 91.00% |
Reino Unido | 6 | 6.00% |
Alemania | 4 | 4.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Larry G. Edwards
- Red Personal